X0306 4 2020-07-17 0 0001807901 Pandion Therapeutics, Inc. PAND 0001465835 Fuglesang Christopher C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE WATERTOWN MA 02472 1 0 1 0 Common Stock 2020-07-21 4 C 0 1408913 A 1408913 I See footnote Common Stock 2020-07-21 4 P 0 722222 18.00 A 2600773 I See footnote Stock Option (right to buy) 18.00 2020-07-17 4 A 0 13997 0.00 A 2030-07-16 Common Stock 13997 13997 D Series B Preferred Stock 2020-07-21 4 C 0 7184596 0.00 D Common Stock 1408913 0 I See footnote Consists of 1,385,291 and 23,622 shares of Common Stock held by Boxer Capital, LLC ("Boxer Capital") and MVA Investors, LLC ("MVA Investors"), respectively. The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. These securities are owned directly by Boxer Capital, and indirectly by the reporting person, Boxer Management and Joe Lewis, by virtue of their ownership in Boxer Capital. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. The reporting person is a member of MVA Investors. Mr. Fuglesang disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date. /s/ Edward Freedman, as attorney-in-fact for Christopher D. Fuglesang 2020-07-21